Buy CryptoMarketsSpotFuturesGOLDEarnEvent Center
More
Gold vs Crypto
SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of novel immunologySAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of novel immunology

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026

Author: AI Journal
Source: AI Journal
2026/02/10 05:32
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will host an investor call and live webcast to review topline results from the 36-week maintenance period of the ongoing Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, February 10, 2026 at 8:00 am ET / 5:00 am PT. 

Conference Call

The results will be provided in a morning press release and presented during the webcast. Interested participants can access the live webcast at this LINK.

The event, the press release and the slides will also be available on the events section of the Nektar website at https://ir.nektar.com/events-and-presentations/events. A replay of the webcast will be available for at least 30 days following the event.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis, one in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar’s pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer, in several ongoing clinical trials.

Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

Contacts:

For Investors:

Vivian Wu
628-895-0661
VWu@nektar.com 

Corey Davis, Ph.D.
LifeSci Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577

Ahu Demir, Ph.D.
LifeSci Advisors, LLC
ademir@lifesciadvisors.com
212-915-3820

For Media:

Jonathan Pappas
LifeSci Communications
857-205-4403
jpappas@lifescicomms.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-hold-conference-call-to-discuss-topline-results-from-the-36-week-maintenance-period-for-its-rezolve-ad-phase-2b-study-of-rezpegaldesleukin-in-atopic-dermatitis-on-february-10-2026-302682916.html

SOURCE Nektar Therapeutics

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Why It Could Outperform Pepe Coin And Tron With Over $7m Already Raised

Why It Could Outperform Pepe Coin And Tron With Over $7m Already Raised

The post Why It Could Outperform Pepe Coin And Tron With Over $7m Already Raised appeared on BitcoinEthereumNews.com. Crypto News 17 September 2025 | 20:26 While meme tokens like Pepe Coin and established networks such as Tron attract headlines, many investors are now searching for projects that combine innovation, revenue-sharing and real-world utility. BlockchainFX ($BFX), currently in presale at $0.024 ahead of an expected $0.05 launch, is quickly becoming one of the best cryptos to buy today. With $7m already secured and a unique model spanning multiple asset classes, it is positioning itself as a decentralised super app and a contender to surpass older altcoins. Early Presale Pricing Creates A Rare Entry Point BlockchainFX’s presale pricing structure has been designed to reward early participants. At $0.024, buyers secure a lower entry price than later rounds, locking in a cost basis more than 50% below the projected $0.05 launch price. As sales continue to climb beyond $7m, each new stage automatically increases the token price. This built-in mechanism creates a clear advantage for early investors and explains why the project is increasingly cited in “best presales to buy now” discussions across the crypto space. High-Yield Staking Model Shares Platform Revenue Beyond its presale appeal, BlockchainFX is creating a high-yield staking model that gives holders a direct share of platform revenue. Every time a trade occurs on its platform, 70% of trading fees flow back into the $BFX ecosystem: 50% of collected fees are automatically distributed to stakers in both BFX and USDT. 20% is allocated to daily buybacks of $BFX, adding demand and price support. Half of the bought-back tokens are permanently burned, steadily reducing supply. Rewards are based on the size of each member’s BFX holdings and capped at $25,000 USDT per day to ensure sustainability. This structure transforms token ownership from a speculative bet into an income-generating position, a rare feature among today’s altcoins. A Multi-Asset Platform…
Share
BitcoinEthereumNews2025/09/18 03:35
OceanPal, a US-listed company, disclosed in its financial report that it holds 51.3 million NEAR tokens.

OceanPal, a US-listed company, disclosed in its financial report that it holds 51.3 million NEAR tokens.

PANews reported on March 28 that OceanPal, a Nasdaq-listed digital asset management operator, released its annual financial report, which disclosed that its balance
Share
PANews2026/03/28 18:03
Shiba Inu Price Outlook as Shibarium Activity Surges

Shiba Inu Price Outlook as Shibarium Activity Surges

The post Shiba Inu Price Outlook as Shibarium Activity Surges appeared on BitcoinEthereumNews.com. Shibarium activity has accelerated sharply in recent days, drawing
Share
BitcoinEthereumNews2026/03/28 18:01